We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

A Study of BBI503 in Adult Patients With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01781455
Recruitment Status : Completed
First Posted : February 1, 2013
Last Update Posted : April 5, 2022
Information provided by (Responsible Party):
Sumitomo Pharma Oncology, Inc.

Brief Summary:
This is an open label, single arm dose escalation study of BBI503 in adult patients with advanced solid tumors.

Condition or disease Intervention/treatment Phase
Cancer, Advanced Solid Tumors Drug: BBI503 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 311 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Clinical Study of BBI503 in Adult Patients With Advanced Solid Tumors
Study Start Date : February 2012
Actual Primary Completion Date : June 2020
Actual Study Completion Date : June 2020

Arm Intervention/treatment
Experimental: BBI503 Drug: BBI503

Primary Outcome Measures :
  1. Number of participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: Adverse events will be assessed at baseline, while the participant is taking BBI503, and for 30 days after stopping therapy. The average length of this duration is expected to be approximately 4 months. ]
    Assessment of safety of BBI503 by reporting of adverse events and serious adverse events.

  2. Determination of the recommended Phase 2 dose [ Time Frame: Up to treatment discontinuation + 30 days with an estimated treatment duration of 4 weeks ]

Secondary Outcome Measures :
  1. Pharmacokinetic profile (Area under the curve) of BBI503 [ Time Frame: During the first 28 days of treatment ]
    Blood sampling to assess the pharmacokinetic profile (Area under the curve) of BBI503.

  2. Pharmacodynamic activity [ Time Frame: During the first 28 days of treatment ]
    Tumor Biopsy(s) to provide information on analysis of the targets and downstream genes/ effect of BBI503 on cancer stem cells through immunohistochemistry.

  3. Anti-tumor activity [ Time Frame: Participants will be assessed every eight weeks for anti-tumor activity. ]
    To assess the preliminary anti-tumor activity of BBI503.

Other Outcome Measures:
  1. Progression Free Survival [ Time Frame: The time the participant stays on study until progression will be measured and recorded. This is estimated to be approximately 4 months. ]
  2. Overall Survival [ Time Frame: Participant follow-up for overall survival will occur approximately quarterly for the first year the participant is off study, twice during the second year, and once per year thereafter for up to approximately 100 months. ]
    The time of overall survival will be measured and recorded for each participant.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Signed written informed consent must be obtained and documented according to International Conference on Harmonization (ICH)- Good Clinical Practice (GCP), the local regulatory requirements, and permission to use private health information in accordance with the Health Insurance Portability and Accountability Act (HIPPA) prior to study-specific screening procedures
  2. A histologically or cytologically confirmed solid tumor that is metastatic, unresectable, or recurrent and for which standard curative or palliative therapies do not exist or are no longer effective.
  3. ≥ 18 years of age
  4. Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST)
  5. Karnofsky performance status ≥ 70%
  6. Male or female patients of child-producing potential must agree to use contraception or avoidance of pregnancy measures during the study and for 30 days after the last BBI503 dose
  7. Females of childbearing potential must have a negative serum pregnancy test
  8. Aspartate transaminase (AST) and alanine transaminase (ALT) < or equal to 1.5 × upper limit of normal (ULN)
  9. Hemoglobin (Hgb) ≥ 10 g/dl
  10. Total bilirubin < or equal to 1.5 × ULN
  11. Creatinine < or equal to 1.5 x ULN or creatinine clearance > 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal
  12. Absolute neutrophil count < or equal to 1.5 x 10^9/L
  13. Platelets ≥ 100 x 10^9/L
  14. Life expectancy ≥ 3 months

Exclusion Criteria:

  1. Anti-cancer chemotherapy, radiotherapy, immunotherapy, or investigational agents within four weeks of first dose with the exception for a single dose radiation up to 8 Gray (equal to 800 RAD) with palliative intent for pain control up to 14 days before beginning the administration of BBI503
  2. Surgery within 4 weeks prior to first dose
  3. Any known untreated brain metastases. Treated subjects must be stable for 4 weeks after completion of that treatment, with image documentation required. Patients must have no clinical symptoms from brain metastases and must be either off steroids or on a stable dose of steroids for at least 2 weeks prior to protocol enrollment. Patients with known leptomeningeal metastases are excluded, even if treated.
  4. Pregnant or breastfeeding
  5. Significant gastrointestinal disorder(s), in the opinion of the Principal Investigator, (e.g., Crohn's disease, ulcerative colitis, extensive gastric resection and small intestinal resection)
  6. Unable or unwilling to swallow BBI503 capsules daily
  7. Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, clinically significant non-healing or healing wounds, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, significant pulmonary disease (shortness of breath at rest or mild exertion), uncontrolled infection or psychiatric illness/social situations that would limit compliance with study requirements

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01781455

Show Show 19 study locations
Sponsors and Collaborators
Sumitomo Pharma Oncology, Inc.
Layout table for additonal information
Responsible Party: Sumitomo Pharma Oncology, Inc.
ClinicalTrials.gov Identifier: NCT01781455    
Other Study ID Numbers: BBI503-101
First Posted: February 1, 2013    Key Record Dates
Last Update Posted: April 5, 2022
Last Verified: April 2022
Additional relevant MeSH terms:
Layout table for MeSH terms